Navigation Links
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
Date:2/25/2009

PRINCETON, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today its financial results for the quarter and year ended December 31, 2008.

Medarex's net loss for the year ended December 31, 2008, was $38.5 million, or ($0.30) per share, as compared to a net loss of $27.1 million, or ($0.21) per share, for 2007. Medarex's net loss for 2008 includes a gain of $151.8 million, or $1.18 per share, from Medarex's sale of 2.5 million shares of Genmab A/S ("Genmab") stock in February 2008; a non-cash loss of $13.0 million, or ($0.10) per share, representing the loss associated with Medarex's ownership of Celldex Therapeutics, Inc. ("Celldex"); a non-cash charge of $22.1 million, or ($0.17) per share, for stock-based compensation recorded in accordance with FAS 123(R); and a non-cash impairment charge of $5.3 million, or ($0.04) per share, related to a write-down of Medarex's investment in three of its corporate partners. Excluding the impact of these items, Medarex's net loss on a non-GAAP basis for 2008 was $149.9 million, or ($1.17) per share.

Total revenues for the year ended December 31, 2008, decreased by $4.0 million from $56.3 million in 2007 to $52.3 million in 2008. Contract and license revenues increased by $0.4 million for the year ended December 31, 2008, from $35.9 million in 2007 to $36.3 million in 2008. Reimbursement of development costs for the year ended December 31, 2008, decreased by $4.4 million from $20.4 million in 2007 to $16.0 million in 2008 and relates primarily to the development of ipilimumab with Bristol-Myers Squibb Company.

Research and development (R&D) expenses for the year ended December 31, 2008, decreased by $3.4 million from $198.3 million in 2007 to $194.9 million in 2008. Included in R&D expense for the year ended December 31, 2008, is appro
'/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
2. Medarex to Present at the JPMorgan Small/Mid Cap Conference
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
5. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
7. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
8. Medarex Announces 2008 First Quarter Financial Results
9. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
10. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
11. Medarex Reviews Recent Highlights and Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... 29 Four leaders,from the worlds of medicine, research, ... national Board of Trustees of the March of,Dimes Foundation, ... who serve as volunteers, represent the public,in governing the ... The new trustees are:, Miriam Arond, Director of ...
... ROCK, Ark., July 29 Heifer International and,Elanco ... partnership,agreement. Heifer International is a world hunger organization. ... Indiana, that has,offices in 30 countries around the ... animal health and productivity., The partnership will ...
... organized population-based breast cancer screening program in Norway and ... self-referrals in Vermont are equally sensitive for detecting cancer, ... the Journal of the National Cancer Institute . ... in Norway. , Breast cancer screening in the United ...
... Ultra-miniature bialy-shaped particles called nanobialys because they ... popular in New York City could soon ... tumors or atherosclerotic plaques. , The nanobialys ... diagnostic and disease-fighting nanoparticles developed by researchers in ...
... $0.56 Net Income Per Share, SAN JOSE, Calif., ... ), a leading provider of medical devices,for the minimally ... for the second quarter ended June 30, 2008., ... 85% to $31.9,million compared with $17.2 million for the ...
... Q2 net revenues of $79.9 million increase 6.9 percent sequentially ... $0.06 per diluted share - Case ... cost-saving measures including a workforce reduction, SANTA CLARA, Calif., July ... results for the,second quarter of fiscal 2008, ended June 30, 2008., ...
Cached Medicine News:Health News:Four Named to March of Dimes Board of Trustees 2Health News:Four Named to March of Dimes Board of Trustees 3Health News:Four Named to March of Dimes Board of Trustees 4Health News:Four Named to March of Dimes Board of Trustees 5Health News:Four Named to March of Dimes Board of Trustees 6Health News:Four Named to March of Dimes Board of Trustees 7Health News:Heifer and Elanco Announce Charitable Partnership 2Health News:2 different breast cancer screening strategies are equally effective 2Health News:New disease-fighting nanoparticles look like miniature pastries 2Health News:New disease-fighting nanoparticles look like miniature pastries 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 4Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 5Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 6Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 7Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 8Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 2Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 3Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 4Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 5Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 6Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 7Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 8Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 9Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 10Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 11Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 12Health News:Align Technology Announces Second Quarter Fiscal 2008 Results 13
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... , Dec. 22, 2014 NxStage Medical, ... of innovative dialysis products, announced today that the ... its System One™ to perform hemodialysis overnight while ... home nocturnal hemodialysis. NxStage,s® System One is the ... FDA for this indication. Home ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... results from,a 24-week study presented today at a ... long-acting injection (LAI),therapeutic doses showed a maintenance of ... of pooled safety data from all olanzapine LAI ... Olanzapine LAI is an investigational formulation that combines,Zyprexa(R) ...
... ... Patients, ... (BRNI) have discovered that,Bryostatin -- and a related class of drugs ... repair brain tissue.,These findings are markedly advanced compared to current stroke ...
Cached Medicine Technology:Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 2Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 3Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 4Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 5Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 6Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 7Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 8Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for up to Six Months 9Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue 2
... it is not the Flu? Streptococcus pneumoniae ... "flu-like" infections. The easy-to-use, rapid, urine-based test ... the new 4 hour guidelines. Rapid identification ... patient outcomes and lower overall health care ...
... newest technology available in acrylic lens design. ... material and design properties to achieve truly ... Unique foldable hydrophobic acrylic material , ... , High index of refraction ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Single Use Loading Units (SULU's) Knifeless for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
Medicine Products: